Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 4/20 | 0.35 |
| ▸ | VNN1 | O95497 | 1/20 | 0.34 |
| ▸ | ACLY | P53396 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
| ▸ | KHK | P50053 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL171635 | 0.82 | TRPV4 (0.57) | TRPV4CYP11B1CYP11B2 | |
| SCHEMBL769392 | 0.78 | MAOB (0.42) | TRPV4 | |
| SCHEMBL17787791 | 0.77 | EGFR (0.32) | — | |
| SCHEMBL74807 | 0.76 | TRPV4 (0.46) | TRPV4ARGRM4CNR2PTP4A3 | |
| SCHEMBL1914246 | 0.76 | GRM4 (0.38) | TRPV4GRM4 | |
| SCHEMBL21479818 | 0.75 | CYP11B1 (0.42) | TRPV4ARCYP11B1CYP11B2PGR | |
| SCHEMBL481131 | 0.74 | CYP2A6 (0.46) | TRPV4ARGRM4CYP11B1CYP11B2 | |
| SCHEMBL29998893 | 0.74 | CYP2A6 (0.46) | TRPV4ARGRM4CYP11B1CYP11B2 | |
| SCHEMBL924361 | 0.74 | TRPV4 (0.45) | TRPV4ARGRM4CNR2PTP4A3 | |
| SCHEMBL16122478 | 0.73 | TRPV4 (0.38) | TRPV4KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | GENZYME CORPORATION (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4709716-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORPORATION (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2026-01-08 | — | — | US | disclosed |
| EP-4673141-A1 | NBD1 MODULATORS AND METHODS OF USING THE SAME | Sionna Therapeutics Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2025242566-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2025-11-27 | — | — | WO | disclosed |
| EP-4653430-A1 | AUTOPHAGY INDUCING COMPOUNDS AND USES THEREOF, IN PARTICULAR FOR THE PREVENTION OR TREATMENT OF DISEASES OF THE CNS | Samsara Therapeutics Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4633739-A1 | COMPOUNDS AND COMPOSITION FOR TARGETING TP53-Y220C MUTANTS | Flare Therapeutics, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4583972-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | Sionna Therapeutics Inc. (US) | 2025-07-16 | — | — | EP | disclosed |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | SCHRODINGER, LLC | 2025-06-19 | — | — | US | disclosed |
| WO-2007138355-A1 | PYRROLO[1,2-A]PYRAZIN-1(2H)-ONE AND PYRROLO[1,2-D][1,2,4]TRIAZIN-1(2H)-ONE DERIVATIVES AS INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE(PARP) | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-12-06 | — | — | WO | disclosed |
| EP-1841425-A2 | PHENYL-SUBSTITUTED PYRROLIDONES | IRM LLC A Delware Limited Liability Company (BM) | 2007-10-10 | — | — | EP | disclosed |
| EP-1828194-A1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
| EP-1729771-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2006-12-13 | — | — | EP | disclosed |
| WO-2006081554-A2 | PHENYL-SUBSTITUTED PYRROLIDONES | IRM LLC (BM) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006063708-A1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-15 | — | — | US | disclosed |
| WO-2005094822-A1 | PYRIDYL DERIVATIVES AND THEIR USE AS MGLU5 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12624051-B2 | Macrocyclic compounds, compositions, and methods of using thereof | CFTR, ABCC3, ABCD3 | TRPV4 510/4885AR 3579/4885GRM4 4604/4885 |
| US-20260008786-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | TRPV4 510/4885AR 3579/4885GRM4 4604/4885 |
| US-20260008785-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCC3, ABCD3 | TRPV4 516/4885AR 3367/4885GRM4 4608/4885 |
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA3, GABRA5, GABRA1 | TRPV4 1839/4885AR 240/4885GRM4 76/4885 |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | TRPV4 808/4885AR 356/4885GRM4 83/4885 |
| US-20250197422-A1 | MACROCYCLIC COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF | CFTR, ABCB1, PKD1 | TRPV4 347/4885AR 3330/4885GRM4 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.